MetaCap

Valneva SE ADR (VALN)

NASDAQ: VALNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

5.16-0.205 (-3.82%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VALN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$490.86M
EPS (TTM)
-$2.10
52-week range
4.75 – 12.18
Day range
5.12 – 5.30
Volume / Avg
17.55K / 23.10K
Beta
—
Next earnings
Nov 24, 2026

52-week range

$4.75$12.18

VALN stock today

Shares of Valneva (VALN) finished lower on Nov 20 at $5.16, a drop of 3.82% or $0.205 per share, versus the S&P 500's 3.70% decline. Shares are 57.6% below their 52-week high of $12.18, set on Feb 24, 2026 and 8.6% above the 52-week low of $4.75, near the bottom of the past year's range. VALN is down 41.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 40.1%.

Valneva has posted a net loss over the last twelve months (EPS of -$2.10), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 24 before the market opens; analysts expect EPS of -$0.23.

Summary generated from market data by MetaCap's automated system. Methodology

About Valneva

Company profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Thomas Lingelbach
Headquarters
Saint-Herblain
Employees
620
IPO year
2021

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$12.28+137.98%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $5.10High $18.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 24, 2026
EPS estimate
$-0.23

VALN news

All VALN news

Valneva peers

Health Care sector
VALN peer companies
CompanyPrice% ChgMarket capCompare
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs VALN
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs VALN
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs VALN
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs VALN
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs VALN
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs VALN
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs VALN
DBVTDBV Technologies S.A. ADR9.02-4.25%$566.82Mvs VALN

Indexes, lists and sector

Valneva stock FAQ

What is Valneva's stock price today?

VALN last traded at $5.16 as of Nov 20, 4:00 PM EST, down 3.82% on the day. Prices are delayed at least 15 minutes.

When is Valneva's next earnings date?

Valneva is expected to report earnings on Tuesday, November 24, 2026. Analysts expect EPS of $-0.23.

Who is Valneva's CEO?

Mr. Thomas Lingelbach is the chief executive officer of Valneva SE ADR, which has about 620 employees.

What is the VALN 52-week high?

The 52-week high for VALN is $12.18 and the 52-week low is $4.75. The stock is currently 57.6% below its high.

Compare VALN